Özet:

The relationship between diabetes and cancer is known. In patients with diabetes, the rate of postmenopausal breast cancer has increased. Women with breast cancer are also at risk of developing diabetes. In addition, it has been that thamoxifen used in the treatment of breast cancer in recent period may also play a role in the development of diabetes. Tamoksifen is a nonsteroidal estrogen antagonist that is widely used in the adjuvant hormonal treatment of primary breast cancer. It creates insulin inhibition on the pancreatic beta cells and leads to insulin resistance development. In this observational study, our goal is to perform a retrospective analysis of the tumor incidents followed in our hospital oncology clinic before and after thamoxifen treatment in terms of the development of diabetes and, at the same time, re-examination of the treatment tracking. The tool and method: The retrospective files of patients followed with the diagnosis of breast cancer in our oncology clinic and used in the treatment of thamoxifen were examined. The information was only assessed on the basis of file records. The glukose values of the first and last application before the start of Tamoksifen were assessed. Diabetes patients newly diagnosed were recorded. When the patients were diagnosed with breast cancer, menopausal conditions, recorded and recorded information were recorded. Those who have been diagnosed with diabetes in their CV have not been taken to work. Our study included 44 cases of breast cancer, 30 people were identified as a patient group receiving thamoxifen treatment, 14 people were identified as a control group without thamoxifen treatment. The average age of the incidents included in the study was 50±9.7. The body mass index of 25 people in the patient group was 25 and above. The average duration of use for people using Tamoksifen was 1.88±1.68. In the group of patients we received to study, a new diagnosis of diabetes was observed after thamoxifen treatment in 15 people. In the entire study group, there was a statistically significant difference between the changes in blood glucose values in the veson control (p=0.001). In the control group of patients, the visual control glucose measurement values were statistically significantly higher according to the control group (t=5.661, p < 0.001). The role of diabetes in the development of cancer has been defined and this relationship has been tried to be explained by different mechanisms such as insulin resistance, obesity, eating habits, IGF-1 levels. Animal studies have shown that tamoxyphen increases beta cell apopitosis and reduces insulin secretion. This makes it clear that diabetes has a tendency. In our study, 15 of 30 people under thamoxifen treatment developed a new diagnosis of diabetes. The start of the estrogen receptor of tomoxyphen in positive patients and the exposure to estrogen and therefore the predisposition to diabetes in comparison with those with the negative estrogen receptor of these patients has been claimed to play a role in the development of diabetes. When our study was evaluated in terms of plasma glucose values, the measurements in patients’ latest controls were statistically significantly higher than those who did not use tamoksifen. As a result, our study has shown that prospective randomized-controlled large-scale studies are required to evaluate the effects of thamoxifen in terms of insulin resistance and diabetes development. We believe that the determination of the metabolic profiles of patients before the treatment of Tamoksifen will be predictive in terms of the development of side effects.

Anahtar Kelimeler: